Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
Mateos, Maria-Victoria, Blacklock, Hilary, Schjesvold, Fredrik, Oriol, Albert, Simpson, David, George, Anupkumar, Goldschmidt, Hartmut, Larocca, Alessandra, Chanan-Khan, Asher, Sherbenou, Daniel, AvivLanguage:
english
Journal:
The Lancet Haematology
DOI:
10.1016/S2352-3026(19)30110-3
Date:
July, 2019
File:
PDF, 355 KB
english, 2019